09
Feb

Novartis’ heart failure med LCZ696 has singlehandedly saved the pharma giant’s cardio drug development strategy from the embarrassing setback triggered by serelaxin’s big flop on the regulatory front. The new research is getting some very careful scrutiny now that researchers are suggesting that the drug could possibly be linked to accelerating Alzheimer’s.

…read more

Source: Investigators link Novartis’ would-be cardio blockbuster to Alzheimer’s risk

    

0 No comments